Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 12.5% - What's Next?

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) was up 12.5% during trading on Tuesday . The stock traded as high as $11.62 and last traded at $11.57. Approximately 43,273 shares traded hands during trading, a decline of 83% from the average daily volume of 247,602 shares. The stock had previously closed at $10.28.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on MAZE shares. Leerink Partners started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 target price on the stock. Guggenheim reiterated a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Leerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 target price for the company. Finally, TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $25.67.

Maze Therapeutics Trading Up 9.5%

The company's 50-day moving average is $9.53.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. TRV GP IV LLC bought a new position in Maze Therapeutics in the first quarter valued at approximately $66,874,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Maze Therapeutics during the 1st quarter worth $45,460,000. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics in the first quarter valued at about $45,362,000. Matrix Capital Management Company LP bought a new position in Maze Therapeutics in the first quarter valued at about $27,373,000. Finally, Alphabet Inc. acquired a new position in Maze Therapeutics during the first quarter worth about $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.